2025年逆转录病毒和机会性感染会议：急性和急性后新冠病毒感染
CROI 2025: Acute and Postacute COVID-19.
作者信息
Antar Annukka A R, Peluso Michael J
机构信息
Johns Hopkins University, Baltimore, MD, USA.
University of California San Francisco, San Francisco, CA, USA.
出版信息
Top Antivir Med. 2025 Jun 30;33(3):555-568.
New research on acute and postacute COVID-19 was presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). Results of the SCORPIO-PEP (Stopping COVID-19 Progression With Early Protease Inhibitor Treatment-Postexposure Prophylaxis) study indicated that the protease inhibitor ensitrelvir is effective for postexposure prophylaxis. Results from the second phaseof the Ubuntu study suggested that monovalent or bivalent booster doses of mRNA vaccines are equally protective in people with or without HIV. A phase II study of an inhaled broad-spectrum antiviral small interfering RNA showed faster clearance of virus and more rapid resolution of symptoms with its use. In addition, numerous studies improved our understanding of the long-term consequences of SARS-CoV-2 infection, including immunologic, metabolic, cardiovascular, neurologic, and other clinical sequelae. The application of new and more specific case definitions in research studies of long COVID provided new insights into the epidemiology and pathogenesis of this condition, although data on therapeutics from randomized clinical trials are still lacking.
关于急性和急性后新冠病毒感染的新研究在2025年逆转录病毒与机会性感染会议（CROI）上进行了展示。SCORPIO-PEP（早期蛋白酶抑制剂治疗-暴露后预防阻止新冠病毒进展）研究结果表明，蛋白酶抑制剂恩西司韦对暴露后预防有效。Ubuntu研究第二阶段的结果表明，单价或二价mRNA疫苗加强针在有或没有艾滋病毒的人群中具有同等的保护作用。一项吸入式广谱抗病毒小干扰RNA的II期研究表明，使用该药物可更快清除病毒并更快缓解症状。此外，大量研究增进了我们对新冠病毒感染长期后果的理解，包括免疫、代谢、心血管、神经及其他临床后遗症。尽管仍缺乏来自随机临床试验的治疗数据，但在长期新冠研究中应用新的、更具体的病例定义为该病的流行病学和发病机制提供了新见解。
Zotero 插件